Trump’s Stock Market Obsession Continues, Advice from Top Investor

We highlighted in Why ‘Tariff Man’ Isn’t Happy with Market Reaction to Trade Truce how Trump is excessively focused on stock markets….

IMF and ECB Advocate Central Bank Independence

Despite frequent criticism from Trump, the Fed went ahead with four rate hikes last year.
Align Technology

Align Technology: What to Expect in Q2

Align Technology (ALGN) plans to release its second-quarter earnings on July 24 after the market closes.

How Abbott Stock Reacted to the Company’s Q3 Results

Healthcare giant Abbott Laboratories announced its third-quarter earnings results before markets opened today. Its stock was trading at $83.66 midday.
renaissance technologies

Renaissance Technologies: Analyzing Its Q3 13F

At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies' top five buys.

Appaloosa Management starts new positions in FCX, INGR, CYH, THC and...

In this six-part series, we'll go through some of the main positions Appaloosa Management traded this past quarter. Why buy Tenet Healthcare Corp. (THC)?

Amgen has attractive, high-growth assets

The principal products represented 92% of Amgen's worldwide product sales for the first half of 2014. Total product sales in 3Q14 rose 4% year-over-year, mainly driven by Kyprolis, Prolia, Neulasta, and Xgeva.

Bill Ackman Is ‘Dead Wrong’ for Shorting Herbalife, Says Carl Icahn

Bill Ackman, CEO of Pershing Square Capital Management LP, has been shorting Herbalife (HLF) since 2012.

Wall Street’s Views on Boston Scientific after Its 3Q17 Earnings

Boston Scientific (BSX) released its 3Q17 earnings on October 26. On October 31, BSX received “buy” ratings from 19 of 25 analysts covering its stock.